Discover more from Steve Kirsch's newsletter
If your results are too good, NEJM will reject your paper
And if you write about ivermectin, CUREUS will reject your paper.
Flavio Cadegiani sent me this slide:
Here’s a closer shot of the text (click the image to magnify):
If your results are too good (as in the clinical trial of proxalutamide for treating COVID), NEJM is required to reject your paper even if they can’t find any other problems.
CUREUS will reject your paper if it is about ivermectin (even if Pierre Kory is a co-author). They don’t like to publish on controversial topics. It is better to wait for the censorship to resolve the dispute rather than allow differing points of view to be surfaced in the scientific literature.
That’s how scientific journals work nowadays.
Just thought you’d want to know.